HCW Biologics Inc. HCWB

HCWB Company Overview

HCW Biologics Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer and age-related diseases. The company operates within the biotechnology and immuno-oncology industries and is primarily engaged in the discovery, development, and commercialization of proprietary fusion protein therapeutics designed to modulate the immune system. Its core technology platform centers on the creation of multifunctional biologics intended to activate or regulate immune responses with potentially improved safety and efficacy profiles compared with conventional cytokine therapies.

The company’s principal revenue drivers historically have included research collaborations, licensing arrangements, and capital raised through public markets, as HCW Biologics remains in the clinical development stage and has not reported significant commercial product revenue. HCW Biologics is known for its proprietary TOBI™ and Immuno-Oncology platforms, which are designed to engineer cytokine-based therapeutics for oncology and inflammatory diseases. Founded in 2018 and headquartered in Miramar, Florida, the company evolved from early-stage immunotherapy research into a publicly traded biotechnology firm listed on the Nasdaq Capital Market under the ticker HCWB.